Study backs test for predicting heart disease:
This article was originally published in Clinica
UK company Omega Diagnostics has reported that the first independent clinical trial of its CardioPath test for predicting coronary heart disease has produced positive results. Middle-aged men who tested positive on the assay were linked with a five-to-six times increased risk of developing a coronary event, according to a study by the UK's Medical Research Council Epidemiology and Medial Care Unit in London. The test prototype is currently in an open enzyme immunoassay format and detects the activation of complement, a group of proteins involved in the body's immune system, said Alloa-based Omega.